Technical Analysis for ELYM - Eliem Therapeutics, Inc

Grade Last Price % Change Price Change
D 16.795 1.54% 0.26
ELYM closed up 4.22 percent on Monday, September 27, 2021, on 78 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong N/A N/A Down
Historical ELYM trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 1.54%
Oversold Stochastic Weakness 1.54%
1,2,3 Retracement Bearish Bearish Swing Setup 5.83%
Outside Day Range Expansion 5.83%
Wide Bands Range Expansion 5.83%
Oversold Stochastic Weakness 5.83%
Lower Bollinger Band Walk Weakness 0.99%
Wide Bands Range Expansion 0.99%
Oversold Stochastic Weakness 0.99%
Narrow Range Bar Range Contraction 6.23%
Older End-of-Day Signals for ELYM ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Resistance about 4 hours ago
Up 5% about 5 hours ago
Up 3% about 5 hours ago
Up 2% about 5 hours ago
60 Minute Opening Range Breakout about 5 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Eliem Therapeutics, Inc Description

Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems in the United States. The company's lead clinical-stage candidates include ETX-810, a novel palmitoylethanolamide prodrug that is in Phase IIa clinical trials for the treatment of diabetic peripheral neuropathic pain and pain associated with lumbosacral radiculopathy; and ETX-155 is a neurosteroid GABAA receptor positive allosteric modulator for the treatment of major depressive disorder, perimenopausal depression, and focal onset seizures. Its lead preclinical program includes Kv7.2/3 potassium channel opener for epilepsy and pain; and novel analog of 2,3- benzodiazepine for the treatment of generalized anxiety disorder. The company was incorporated in 2018 and is headquartered in Redmond, Washington.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Pain Neuroscience Disorders Chronic Pain Epilepsy Major Depressive Disorder Neuropathic Pain Neurophysiology Treatment Of Major Depressive Disorder Gabaa Receptor Positive Allosteric Modulators Peripheral Neuropathy Perimenopausal Depression

Is ELYM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 29.48
52 Week Low 13.65
Average Volume 269,633
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 22.49
10-Day Moving Average 18.74
Average True Range 3.01
ADX 36.32
+DI 16.78
-DI 22.96
Chandelier Exit (Long, 3 ATRs) 20.46
Chandelier Exit (Short, 3 ATRs) 24.02
Upper Bollinger Bands 31.93
Lower Bollinger Band 13.06
Percent B (%b) 0.18
BandWidth 83.92
MACD Line -0.99
MACD Signal Line 0.24
MACD Histogram -1.2258
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.88
Resistance 3 (R3) 18.66 17.67 18.49
Resistance 2 (R2) 17.67 17.07 17.78 18.36
Resistance 1 (R1) 17.10 16.70 17.39 17.32 18.23
Pivot Point 16.11 16.11 16.25 16.22 16.11
Support 1 (S1) 15.54 15.51 15.83 15.76 14.85
Support 2 (S2) 14.55 15.14 14.66 14.72
Support 3 (S3) 13.98 14.55 14.59
Support 4 (S4) 14.20